Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Costanzo Feo"'
Autor:
Roberto Latagliata, Fabio Stagno, Mario Annunziata, Elisabetta Abruzzese, Alessandra Iurlo, Attilio Guarini, Carmen Fava, Antonella Gozzini, Massimiliano Bonifacio, Federica Sorà, Sabrina Leonetti Crescenzi, Monica Bocchia, Monica Crugnola, Fausto Castagnetti, Isabella Capodanno, Sara Galimberti, Costanzo Feo, Raffaele Porrini, Patrizia Pregno, Manuela Rizzo, Agostino Antolino, Endri Mauro, Nicola Sgherza, Luigiana Luciano, Mario Tiribelli, Antonella Russo Rossi, Malgorzata Trawinska, Paolo Vigneri, Massimo Breccia, Gianantonio Rosti, Giuliana Alimena
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 18, Iss 9, Pp 536-540 (2016)
Dasatinib (DAS) has been licensed for the frontline treatment in chronic myeloid leukemia (CML). However, very few data are available regarding its efficacy and toxicity in elderly patients with CML outside clinical trials. To address this issue, we
Externí odkaz:
https://doaj.org/article/cf326cb4083d49d69854ac476b662cf8
Autor:
Gioia Colafigli, Monica Crugnola, Ida Carmosino, Nicola Sgherza, Mario Tiribelli, Federica Sorà, Sara Galimberti, Cristina Bucelli, Fabio Stagno, Mario Annunziata, Roberto Latagliata, Alessandra Iurlo, Antonella Russo Rossi, Malgorzata Monika Trawinska, Luigiana Luciano, Carmen Fava, Costanzo Feo, Antonella Gozzini, Francesco Di Raimondo, Sabrina Leonetti Crescenzi, Massimiliano Bonifacio, Gianantonio Rosti, Attilio Guarini, Massimo Breccia, Endri Mauro, Gabriele Gugliotta, Elisabetta Abruzzese
Publikováno v:
Acta oncologica (Stockholm, Sweden). 60(11)
A limited amount of data has been published in chronic-phase chronic myeloid leukemia (CP-CML) patients aged75 years treated frontline with second-generation tyrosine kinase inhibitors.To address this issue in a clinical 'real-life' setting, we retro
Autor:
Raffaele Porrini, Monica Bocchia, Fabio Stagno, Patrizia Pregno, Elisabetta Abruzzese, Attilio Guarini, Agostino Antolino, Mario Tiribelli, Antonella Russo Rossi, Nicola Sgherza, Malgorzata Monika Trawinska, Sabrina Leonetti Crescenzi, Gianantonio Rosti, Fausto Castagnetti, Luigiana Luciano, Massimo Breccia, Monica Crugnola, Isabella Capodanno, Roberto Latagliata, Carmen Fava, Sara Galimberti, Massimiliano Bonifacio, Costanzo Feo, Giuliana Alimena, Manuela Rizzo, Endri Mauro, Federica Sorà, Paolo Vigneri, Alessandra Iurlo, Mario Annunziata, Antonella Gozzini
Publikováno v:
Neoplasia (New York, N.Y.)
Neoplasia: An International Journal for Oncology Research, Vol 18, Iss 9, Pp 536-540 (2016)
Neoplasia: An International Journal for Oncology Research, Vol 18, Iss 9, Pp 536-540 (2016)
Dasatinib (DAS) has been licensed for the frontline treatment in chronic myeloid leukemia (CML). However, very few data are available regarding its efficacy and toxicity in elderly patients with CML outside clinical trials. To address this issue, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40e95e05cdb7ee2ad44b6a72961dee0f
http://hdl.handle.net/2318/1610276
http://hdl.handle.net/2318/1610276
Autor:
Roberto Latagliata, Nicola Sgherza, Gabriele Gugliotta, Carmen Fava, Alessandra Iurlo, Paolo Vigneri, Gianfranco Giglio, Isabella Capodanno, Attilio Guarini, Sabrina Leonetti Crescenzi, Costanzo Feo, Giuliana Alimena, Mario Annunziata, Sara Galimberti, Fabio Stagno, Antonella Gozzini, Patrizia Pregno, Monica Crugnola, Malgorzata Monika Trawinska, Monica Bocchia, Massimo Breccia, Federica Sorà, Raffaele Porrini, Elisabetta Abruzzese
Background Dasatinib has been recently licensed for first line treatment of patients with chronic myeloid leukemia (CML). However, very few data are available as to toxicity and efficacy of dasatinib in unselected elderly CML patients. Aim To address
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::648f681450a61431b2fe5e8d06a40a3e
http://hdl.handle.net/11568/680299
http://hdl.handle.net/11568/680299
Autor:
Federica Sorà, Carmen Fava, Gianni Binotto, Paolo Vigneri, Costanzo Feo, Giuliana Alimena, Mario Tiribelli, Elena Crisà, Antonella Gozzini, Pellegrino Musto, Mario Annunziata, Roberto Latagliata, Luigiana Luciano, Francesco Cavazzini, Ubaldo Occhini, Antonella Russo Rossi, Valeria Santini, Fausto Castagnetti, Enrico Montefusco, Fabio Stagno, Patrizia Pregno, Massimo Breccia, Elisabetta Abruzzese, Giannantonio Rosti, Stefano Ulisciani
To highlight dasatinib role in the elderly, 125 unselected patients with CP-CML aged >60 years resistant/intolerant to imatinib were retrospectively evaluated. Grade 3-4 haematological and extra-haematological toxicities were reported in 39 (31.2%) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::818d097438c0fae7b3047e069c60cc0b
http://hdl.handle.net/20.500.11769/42786
http://hdl.handle.net/20.500.11769/42786
Autor:
Costanzo Feo, Roberto Vallone, Bruno Rotoli, David Pagnini, Giuseppe Caparrotti, Lucio Catalano
Publikováno v:
The Hematology Journal. 4:459-460
(38%) MC increase (median 13.5%, range 1.2–34.7). Among the 13 patients in the control group, four (31%) had MC decrease (median 20.3%, range 9.1–27.3 and nine (69%) MC increase (median 19.2%, range 1.5–43.2). Patients showing MC reduction duri